The ultimate goal in drug discovery is to identify the mechanistic cause of a disease, develop a therapeutic to target it, and then test the efficacy in humans with the condition. But it’s rarely that easy, and each step can take years or even decades.
Antonella De Matteis’ lab appears to be successfully following this path for Lowe syndrome, a rare X-linked disorder with mutations in the OCLR gene that causes issues with the eyes, brain, and kidneys. After 20 years of studying the mechanistic cause of the disease, her lab has now identified a novel biological cause behind the kidney disease aspect and demonstrated that a repurposed drug can target it in patient-derived cells, kidney organoids, and animal models. Their work was published recently in Signal Transduction and Targeted Therapy.
The findings will likely lead to the first drug in clinical trials for Lowe syndrome, if the Italian Medicines Agency accepts the Phase 2 submission from Can-Fite BioPharma.
”We now finally have a tangible opportunity to offer people living with Lowe syndrome and their families, who have supported our work throughout these years, a real prospect for the future,” Leopoldo Staiano, a molecular biologist at the Telethon Institute of Genetics and Medicine and the CNR Institute of Genetic and Biomedical Research, and the first author of the study, said in the press release.
Finding the drug
The OCRL gene codes for PI(4,5)P₂ 5-phosphatase OCRL, an enzyme that is essential in the production of phosphoinositides — lipids that regulate membrane trafficking and organelle identities.
To find a new therapeutic strategy, the research team used a screening platform with 1,200 compounds to see which ones could restore phosphoinositide homeostasis. They found that they could repurpose piclidenoson, an adenosine A3 receptor agonist that has already been studied in clinical trials to treat conditions like plaque psoriasis and rheumatoid arthritis.
Across testing in patient-derived renal tubular kidney cells, human kidney organoids, single-cell RNA-seq datasets, and mouse models, De Matteis’ team showed that piclidenoson achieved phosphoinositide homeostasis through normalizing receptor trafficking and protein reabsorption. They also were able to reveal the mechanism behind it: Piclidenoson activates the A3 receptor and supports the breakdown of PI(4,5)P₂ through an alternate pathway separate from OCRL.
“The real challenge was not simply to identify a drug, but to build a pathway linking the understanding of a molecular mechanism to a tangible benefit for patients,” said De Matteis in the press release.
As a result, the therapeutic focus on activating the A3 receptor differs from everything else tried before; prior approaches have all focused on inhibiting the enzymes related to phosphoinositide metabolism.
“This is not ‘just’ a case of drug repurposing: we have above all uncovered a novel biological mechanism that could correct a pathological imbalance at the root of the disease,” said Staiano.
The first potential drug in a clinical trial for Lowe syndrome
Given piclidenoson’s tolerable safety profile in other clinical trials, the researchers have already partnered with Can-Fite BioPharma and Fondazione Telethon to move forward with a small Phase 2 trial to test the ability of the drug to improve renal tubular function in Lowe syndrome patients. The study, which proposes to dose oral piclidenoson twice daily for six months, is currently still under review at the Italian Medicines Agency.
"The initiation of our first clinical program in Lowe syndrome represents an important milestone for Can-Fite," said Motti Farbstein, CEO of Can-Fite BioPharma in the announcement back in August. "Supported by compelling preclinical data, this focused Phase 2 pilot study is designed to facilitate discussions with regulatory authorities regarding the clinical development and potential registration pathway for Piclidenoson in Lowe syndrome.”
The scientists are also hopeful that their findings around using an A3 agonist to correct phosphoinositide homeostasis could expand beyond Lowe syndrome, as many other rare genetic diseases, like Charcot–Marie–Tooth disease and X-linked myotubular myopathy, are also associated with mutations in related enzymes.
“The principle identified in this study could also have future applications for the neurological manifestations of Lowe syndrome and, more broadly, for other diseases characterized by defects in intracellular trafficking. This project highlights the value of an integrated approach that combines cell biology, drug screening, organoids, genomics, animal models, and clinical collaborations,” said De Matteis.









